Bumetanide for autism spectrum disorder: Current evidence

References (13)

1. Baio J, Wiggins L, Christensen DL, Maenner MJ, Daniels J, Warren Z, et al. Prevalence of Autism Spectrum Disorder Among Children Aged 8 Years - Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2014. MMWR Surveill Summ 2018;67(6):1-23
2. Brater DC. Pharmacology of diuretics. Am J Med Sci 2000;319(1):38-50
3. Lemonnier E, Ben-Ari Y. The diuretic bumetanide decreases autistic behaviour in five infants treated during 3 months with no side effects. Acta Paediatr 2010;99(12):1885-8
4. Lemonnier E, Degrez C, Phelep M, Tyzio R, Josse F, Grandgeorge M, et al. A randomised controlled trial of bumetanide in the treatment of autism in children. Transl Psychiatry 2012;2:e202
5. Du L, Shan L, Wang B, Li H, Xu Z, Staal WG, et al. A Pilot Study on the Combination of Applied Behavior Analysis and Bumetanide Treatment for Children with Autism. J Child Adolesc Psychopharmacol 2015;25(7):585-8
6. Lemonnier E, Villeneuve N, Sonie S, Serret S, Rosier A, Roue M, et al. Effects of bumetanide on neurobehavioral func-tion in children and adolescents with autism spectrum disorders. Transl Psychiatry 2017;7(3):e1056
7. Zhang L, Huang C-C, Dai Y, Luo Q, Ji Y, Wang K, et al. Symptom improvement in children with autism spectrum disorder following bumetanide administration is associated with decreased GABA/glutamate ratios. Transl Psychiatry 2020;10(1):9
8. Grandgeorge M, Lemonnier E, Degrez C, Jallot N. The effect of bumetanide treatment on the sensory behaviours of a young girl with Asperger syndrome. BMJ Case Rep 2014;2014
9. Damier P, Hammond C, Ben-Ari Y. Bumetanide to Treat Parkinson Disease: A Report of 4 Cases. Clin Neuropharmacol. 2016;39(1):57-9
10. Rahmanzadeh R, Eftekhari S, Shahbazi A, Khodaei Ardakani MR, Rahmanzade R, Mehrabi S, et al. Effect of bumetanide, a selective NKCC1 inhibitor, on hallucinations of schizophrenic patients; a double-blind randomized clinical trial. Schizophr Res 2017;184:145-6
11. Cellot G, Cherubini E. GABAergic signaling as therapeutic target for autism spectrum disorders. Front Pediatr 2014;2:70-
12. Hadjikhani N, Asberg Johnels J, Lassalle A, Zurcher NR, Hippolyte L, Gillberg C, et al. Bumetanide for autism: more eye contact, less amygdala activation. Sci Rep 2018;8(1):3602
13. Hadjikhani N, Zurcher NR, Rogier O, Ruest T, Hippolyte L, Ben-Ari Y, et al. Improving emotional face perception in autism with diuretic bumetanide: a proof-of-concept behavioral and functional brain imaging pilot study. Auti